AP2001002192A0 - Substituted bicyclic derivatives for the treatment of abnormal cell growth. - Google Patents
Substituted bicyclic derivatives for the treatment of abnormal cell growth.Info
- Publication number
- AP2001002192A0 AP2001002192A0 APAP/P/2001/002192A AP2001002192A AP2001002192A0 AP 2001002192 A0 AP2001002192 A0 AP 2001002192A0 AP 2001002192 A AP2001002192 A AP 2001002192A AP 2001002192 A0 AP2001002192 A0 AP 2001002192A0
- Authority
- AP
- ARIPO
- Prior art keywords
- treatment
- cell growth
- abnormal cell
- substituted bicyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21313600P | 2000-06-22 | 2000-06-22 | |
| PCT/IB2001/001046 WO2001098277A2 (en) | 2000-06-22 | 2001-06-14 | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2001002192A0 true AP2001002192A0 (en) | 2002-12-21 |
Family
ID=22793862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2001/002192A AP2001002192A0 (en) | 2000-06-22 | 2001-06-14 | Substituted bicyclic derivatives for the treatment of abnormal cell growth. |
Country Status (43)
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| PT1117653E (pt) | 1998-10-01 | 2003-06-30 | Astrazeneca Ab | Derivados de quinolina e quinazolina e sua utilizacao como inibidores de doencas mediadas pela citosina |
| CZ20023951A3 (cs) * | 2000-06-22 | 2004-01-14 | Pfizer Products Inc. | Substituované bicyklické deriváty pro léčení abnormálního buničného růstu |
| CA2442742A1 (en) * | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Quinazoline derivatives |
| US20030144308A1 (en) * | 2001-09-24 | 2003-07-31 | Bauer Paul H. | Fructose 1,6-bisphosphatase inhibitors |
| KR20040054813A (ko) * | 2001-11-30 | 2004-06-25 | 화이자 프로덕츠 인코포레이티드 | 비정상적 세포성장을 치료하기 위한 치환된 비사이클릭유도체의 제조방법 |
| HUP0402662A2 (hu) | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk |
| BR0214499A (pt) * | 2001-12-12 | 2005-05-10 | Pfizer Prod Inc | Derivados de quinazolina para o tratamento do crescimento anormal das células |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| JP4703183B2 (ja) | 2002-07-15 | 2011-06-15 | シンフォニー エボルーション， インク． | 受容体型キナーゼモジュレーターおよびその使用方法 |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| NZ540092A (en) | 2002-11-20 | 2007-06-29 | Array Biopharma Inc | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| RU2005119172A (ru) * | 2002-12-18 | 2006-01-20 | Пфайзер Продактс Инк. (Us) | Производные 4-анилинхиназолина для лечения патологического роста клеток |
| KR20050085835A (ko) * | 2002-12-19 | 2005-08-29 | 화이자 프로덕츠 인코포레이티드 | Ｅ-2-메톡시-ｎ-（3-｛4-［3-메틸-4-（6-메틸-피리딘-3-일옥시）-페닐아미노］-퀴나졸린-6-일｝-알릴）-아세트아마이드의 착물, 및 그의 제조방법 및 용도 |
| RS20050652A (en) * | 2003-04-09 | 2007-11-15 | Pfizer Products Inc., | Process for the preparation of n- (((pyridinyloxy)- phenylamino)quinazolinyl)- alyl)acetamide derivatives and related compounds as well as intermediates of such processes and processes for the preparation of such intermediates |
| EP1636195A1 (en) * | 2003-05-27 | 2006-03-22 | Pfizer Products Inc. | Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| JP5129957B2 (ja) * | 2003-07-03 | 2013-01-30 | ミリアド ジェネティクス， インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン |
| CN1822853A (zh) * | 2003-07-15 | 2006-08-23 | 加拿大国家研究委员会 | 用于治疗特征在于过度增殖皮肤细胞的疾病的人类甲状旁腺激素环状类似物 |
| NZ545459A (en) * | 2003-08-14 | 2009-12-24 | Array Biopharma Inc | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| CA2536140A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| AU2004275842B2 (en) | 2003-09-26 | 2010-09-02 | Exelixis Inc. | c-MET modulators and methods of use |
| BRPI0416190A (pt) * | 2003-11-06 | 2007-01-23 | Pfizer Prod Inc | combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro |
| US7632840B2 (en) | 2004-02-03 | 2009-12-15 | Astrazeneca Ab | Quinazoline compounds for the treatment of hyperproliferative disorders |
| US20050192298A1 (en) * | 2004-02-27 | 2005-09-01 | Pfizer Inc | Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide |
| EP2322217A3 (en) | 2004-07-16 | 2011-09-28 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody |
| CN101010304A (zh) * | 2004-09-01 | 2007-08-01 | 三菱制药株式会社 | 分子伴侣功能调节剂 |
| WO2006071079A1 (en) * | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| KR100990027B1 (ko) | 2005-04-26 | 2010-10-26 | 화이자 인코포레이티드 | Ｐ-카드헤린 항체 |
| CA2610491A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Bicyclic derivatives for the treatment of abnormal cell growth |
| EP1896030A1 (en) * | 2005-06-03 | 2008-03-12 | Pfizer Products Incorporated | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| PE20080035A1 (es) | 2005-09-07 | 2008-01-30 | Amgen Fremont Inc | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina |
| US8648087B2 (en) | 2005-11-15 | 2014-02-11 | Array Biopharma, Inc. | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| GB0526552D0 (en) * | 2005-12-29 | 2006-02-08 | Morvus Technology Ltd | New use |
| WO2007132307A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
| WO2008002039A1 (en) * | 2006-06-28 | 2008-01-03 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting the growth of cancer cell |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| JP2010502743A (ja) * | 2006-09-11 | 2010-01-28 | キュリス，インコーポレイテッド | 抗増殖薬剤としての多機能性低分子 |
| MX2009002585A (es) | 2006-09-11 | 2009-08-24 | Curis Inc | Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc. |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| KR20090090336A (ko) | 2006-12-12 | 2009-08-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 융합된 헤테로시클릭 화합물 |
| EP2118075A1 (de) | 2007-02-06 | 2009-11-18 | Boehringer Ingelheim International GmbH | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| AU2008239594B2 (en) | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| RS52573B (en) | 2008-02-07 | 2013-04-30 | Boehringer Ingelheim International Gmbh | SPIROCYCLIC HETEROCYCLES, THE MEDICINAL PRODUCTS CONTAINING THIS UNIT, THEIR APPLICATION AND THE PROCEDURE FOR THEIR MANUFACTURING |
| PE20091580A1 (es) | 2008-03-12 | 2009-11-05 | Takeda Pharmaceutical | Compuesto heterociclico fusionado |
| US8426430B2 (en) * | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
| EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| KR20210151988A (ko) | 2009-01-16 | 2021-12-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| US20120157471A1 (en) | 2009-09-01 | 2012-06-21 | Pfizer Inc. | Benzimidazole derivatives |
| US8993634B2 (en) | 2010-06-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to Her2/neu receptor complex |
| WO2011153050A1 (en) | 2010-06-02 | 2011-12-08 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to her2/neu receptor complex |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| ES2543151T3 (es) | 2010-10-20 | 2015-08-17 | Pfizer Inc | Derivados de 2-piridina como moduladores del receptor Smoothened |
| ES2575710T3 (es) | 2011-09-22 | 2016-06-30 | Pfizer Inc | Derivados de pirrolopirimidina y purina |
| CN102872018B (zh) * | 2012-10-23 | 2015-07-15 | 广州市恒诺康医药科技有限公司 | 酪氨酸激酶不可逆抑制剂及其制备方法和用途 |
| US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
| UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
| WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
| DK3137460T3 (da) | 2014-04-30 | 2019-12-16 | Pfizer | Cycloalkyl-bundne diheterocyklusderivater |
| KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
| WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
| WO2017003668A1 (en) | 2015-07-01 | 2017-01-05 | California Institute Of Technology | Cationic mucic acid polymer-based delivery systems |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| CN115057861A (zh) | 2016-03-01 | 2022-09-16 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| WO2019241327A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
| HRP20240293T1 (hr) | 2018-09-18 | 2024-05-24 | F. Hoffmann - La Roche Ag | Derivati kinazolina kao protutumorska sredstva |
| TW202345816A (zh) * | 2022-03-28 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW321649B (US20070244113A1-20071018-C00138.png) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| DK1119567T3 (da) | 1998-10-08 | 2005-07-25 | Astrazeneca Ab | Quinazolinderivater |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| CZ20023951A3 (cs) * | 2000-06-22 | 2004-01-14 | Pfizer Products Inc. | Substituované bicyklické deriváty pro léčení abnormálního buničného růstu |
-
2001
- 2001-06-14 CZ CZ20023951A patent/CZ20023951A3/cs unknown
- 2001-06-14 KR KR1020027017489A patent/KR100545537B1/ko not_active IP Right Cessation
- 2001-06-14 AU AU2001264159A patent/AU2001264159A1/en not_active Abandoned
- 2001-06-14 DZ DZ013407A patent/DZ3407A1/fr active
- 2001-06-14 JP JP2002504233A patent/JP4044839B2/ja not_active Expired - Fee Related
- 2001-06-14 UA UA20021210405A patent/UA73990C2/uk unknown
- 2001-06-14 WO PCT/IB2001/001046 patent/WO2001098277A2/en active Application Filing
- 2001-06-14 AT AT01938484T patent/ATE288431T1/de not_active IP Right Cessation
- 2001-06-14 DK DK01938484T patent/DK1292591T3/da active
- 2001-06-14 CN CN01811470A patent/CN1437594A/zh active Pending
- 2001-06-14 CN CNA200810144110XA patent/CN101348467A/zh active Pending
- 2001-06-14 HU HU0301120A patent/HUP0301120A2/hu unknown
- 2001-06-14 NZ NZ522568A patent/NZ522568A/xx unknown
- 2001-06-14 PT PT01938484T patent/PT1292591E/pt unknown
- 2001-06-14 BR BR0111548-0A patent/BR0111548A/pt not_active IP Right Cessation
- 2001-06-14 CA CA002413424A patent/CA2413424C/en not_active Expired - Fee Related
- 2001-06-14 YU YU95102A patent/YU95102A/sh unknown
- 2001-06-14 AP APAP/P/2001/002192A patent/AP2001002192A0/en unknown
- 2001-06-14 EA EA200201277A patent/EA005525B1/ru not_active IP Right Cessation
- 2001-06-14 OA OA1200200382A patent/OA12291A/en unknown
- 2001-06-14 SK SK1710-2002A patent/SK17102002A3/sk unknown
- 2001-06-14 MX MXPA02012870A patent/MXPA02012870A/es active IP Right Grant
- 2001-06-14 EP EP01938484A patent/EP1292591B1/en not_active Expired - Lifetime
- 2001-06-14 GE GE5023A patent/GEP20063831B/en unknown
- 2001-06-14 EE EEP200200710A patent/EE200200710A/xx unknown
- 2001-06-14 IL IL15298501A patent/IL152985A0/xx unknown
- 2001-06-14 CN CNB2004100696071A patent/CN1330640C/zh not_active Expired - Fee Related
- 2001-06-14 ES ES01938484T patent/ES2236240T3/es not_active Expired - Lifetime
- 2001-06-14 DE DE60108754T patent/DE60108754T2/de not_active Expired - Lifetime
- 2001-06-14 PL PL01359557A patent/PL359557A1/xx not_active Application Discontinuation
- 2001-06-18 US US09/883,752 patent/US6890924B2/en not_active Expired - Fee Related
- 2001-06-20 AR ARP010102936A patent/AR032353A1/es unknown
- 2001-06-20 MY MYPI20012895 patent/MY127181A/en unknown
- 2001-06-20 PA PA20018520301A patent/PA8520301A1/es unknown
- 2001-06-20 PE PE2001000598A patent/PE20020257A1/es not_active Application Discontinuation
- 2001-06-21 SV SV2001000504A patent/SV2002000504A/es not_active Application Discontinuation
- 2001-06-21 TN TNTNSN01091A patent/TNSN01091A1/fr unknown
-
2002
- 2002-11-12 BG BG107269A patent/BG107269A/bg unknown
- 2002-11-14 IS IS6616A patent/IS6616A/is unknown
- 2002-12-13 HR HR20021005A patent/HRP20021005A2/xx not_active Application Discontinuation
- 2002-12-13 EC EC2002004393A patent/ECSP024393A/es unknown
- 2002-12-16 MA MA26954A patent/MA26914A1/fr unknown
- 2002-12-18 ZA ZA200210231A patent/ZA200210231B/en unknown
- 2002-12-20 NO NO20026166A patent/NO20026166L/no unknown
-
2005
- 2005-03-11 HK HK05102099A patent/HK1069576A1/xx not_active IP Right Cessation
- 2005-03-14 US US11/079,648 patent/US7332493B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2001002192A0 (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth. | |
| MXPA05006420A (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal. | |
| MY124390A (en) | Substituted bicyclic derivatives useful as anticancer agents | |
| YU30702A (sh) | Novi derivati benzoimidazola, korisni agensi protiv proliferacije | |
| RS20050180A (en) | Novel benzoimidazole derivatives useful as antiproliferative agensts | |
| ATE260263T1 (de) | Heteroaromatische bizyklische verbindungen mit antikrebswirkung | |
| GT199900139A (es) | Derivados de quinolin-2-ona ùtiles como agentes contra el càncer. | |
| WO2006067614A3 (en) | Heteroaromatic derivatives useful as anticancer agents | |
| BG104998A (en) | Isothiazole derivatives useful as anticancer agents | |
| TW200630361A (en) | Integrin antagonists useful as anticancer agents | |
| AP2001002079A0 (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents. | |
| MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
| TNSN02096A1 (en) | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| DE69734678D1 (de) | 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung | |
| NZ507452A (en) | Hygromycin a derivatives | |
| MXPA03002595A (es) | Aminoalquilpirrolidinas ligandos del receptor de serotonina y composiciones, sus usos farmaceuticos, y metodos para su sintesis. | |
| AP9901559A0 (en) | Tricyclic 3-keto derivatives of 6-0-methylerythromycin. | |
| AP2001002154A0 (en) | Hygromycin a derivatives (changed by the ISA to read hygromycin a derivatives as antibacterial agents. | |
| MXPA02011966A (es) | Derivados de higromicina a para el el tratamiento de infecciones bacterianas y por protozoarios. | |
| AP2002002492A0 (en) | Hygromycin a prodrugs. | |
| UY26785A1 (es) | Derivados bicíclicos sustituidos para el tratamiento del crecimiento celular anormal |